LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast of the presentation will be accessible here and ...

Group 1 - Mesa Laboratories, Inc. will release its financial results for the third quarter of fiscal year 2026 on February 3, 2026, at 8:00 A.M. Eastern Time [1] - Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [2] - The company provides products and services aimed at ensuring product integrity, increasing patient and worker safety, and improving quality of life globally [2] Group 2 - The press release regarding the financial results will be available to the public [1] - Mesa Laboratories' leadership includes Gary Owens as President and CEO and John Sakys as CFO [3] - For further information, Mesa Laboratories can be contacted at 1-303-987-8000 or through their website [3]

Core Insights - Diamond Hill Capital's "Small Cap Strategy" underperformed the Russell 2000 Index in Q3 2025, returning 7.93% compared to the index's over 12% gain [1] - The underperformance was attributed to the rally being driven by sectors not typically held in the portfolio [1] Company Overview: Mesa Laboratories, Inc. (NASDAQ:MLAB) - Mesa Laboratories, Inc. is a provider of life sciences tools and quality control products and services [2][3] - The stock experienced a one-month return of -0.22% and a 52-week loss of 33.24%, closing at $77.74 with a market capitalization of $429.304 million on November 24, 2025 [2] Performance Analysis - In Q3 2025, Mesa Laboratories was among the bottom contributors to the portfolio, facing challenges such as currency impacts, tariffs, and order timing delays [3] - Despite these challenges, the sterilization and disinfection control segment showed solid core growth, indicating resilience in the company's diversified portfolio [3] Hedge Fund Interest - Mesa Laboratories was held by 12 hedge fund portfolios at the end of Q2 2025, an increase from 8 in the previous quarter [4] - While the company has potential as an investment, certain AI stocks are viewed as offering greater upside potential with less downside risk [4]

Core Insights - Mesa Laboratories (MLAB) shares have experienced a significant decline of 60% from their 2021 highs, trading just over $100 at the time of the analysis, indicating potential recovery opportunities in the stock [1]. Group 1 - The analysis suggests that green shoots are emerging for Mesa Laboratories, signaling a potential turnaround after a substantial drop in share price [1]. - The investment group "Value In Corporate Events" focuses on identifying actionable investment opportunities through major corporate events such as IPOs, mergers & acquisitions, and earnings reports [1]. - The group provides coverage of approximately 10 major events each month, aiming to find the best investment opportunities for its members [1].

Summary of Mesa Laboratories Conference Call Company Overview - **Company**: Mesa Laboratories (NasdaqGS:MLAB) - **Date**: November 20, 2025 Key Industry Insights - **Biopharmaceutical Development**: Experienced a **17% growth** in the quarter, with a **6.4% growth** for the full year, slightly below expectations due to tariff negotiations affecting product shipments from Sweden to the U.S. [1][1] - **Clinical Genomics**: Growth was disappointing overall, with **double-digit growth** in North America and Europe, but a **60% decline** in China, leading to an overall **5% growth** for the quarter and **4% for the year** [2][2][3][3]. - **Calibration Solutions**: Noted **10%+ growth**, attributed to pricing benefits and regaining market share, particularly in North America and internationally [6][6][8][8]. Financial Performance - **Margins**: The business is composed of **75% protein analytics** and **25% peptides**, with peptides growing over **40%** but at lower margins. Expected gross margins to improve from the **high 50s** to **low 60s** in the second half of the year [13][13]. - **Cost Management**: Implemented **$3 million** in cost reductions while reinvesting **$900,000** back into the business to enhance long-term growth [14][15]. Market Dynamics - **Clinical Trials**: The number of clinical trial starts has been flat, but an increase is expected to contribute positively to long-term growth [10][12]. - **Capital Expenditure**: No constraints observed in biopharma capital equipment spending, with a significant recovery from a **15% drop** in clinical trial starts in 2023 [20][21]. - **M&A Landscape**: The market is quieter, with a shift from small caps to large caps, and a focus on value-added acquisitions as leverage decreases [23][25]. Strategic Initiatives - **Expansion in APAC**: Focus on local biotechs in China and expanding support in Korea and Indonesia, with a strategy to enhance clinical trial support [29][30]. - **GKE Integration**: The acquisition of GKE is performing well, with successful cross-selling opportunities in sterility testing [26][27]. Future Outlook - **Sequential Growth**: Anticipation of sequential revenue growth in Q3, driven by backlog improvements and sales momentum [34][35]. - **Long-term Growth**: The company aims to return to growth rates seen in 2017-2018, with expectations for a better 2026 [36][36]. Additional Insights - **Technical Support**: Emphasis on providing high technical support to differentiate from competitors, leading to long-term customer relationships [32][33]. - **Market Adaptation**: Adjustments made in response to tariff and currency changes, with a focus on operational efficiency and market engagement [15][15]. This summary encapsulates the key points discussed during the Mesa Laboratories conference call, highlighting the company's performance, market dynamics, strategic initiatives, and future outlook.

Core Insights - Mesa Laboratories, Inc. announced participation in several upcoming conferences, indicating active engagement with investors and stakeholders [1] - The company is a leader in life science tools and quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [2] Conference Participation - Mesa Laboratories will attend the Raymond James Napa Valley Small Cap Symposium on November 17, 2025, in a 1x1 meeting format [1] - The Jefferies London Healthcare Conference will feature a fireside chat with Mesa's executives on November 20, 2025, at 12:00 p.m. GMT, accessible via live webcast [1] - The 8th Annual Evercore Healthcare Conference will also include a fireside chat on December 3, 2025, at 2:10 p.m. ET [1] Company Overview - Mesa Laboratories specializes in designing and manufacturing life science tools and critical quality control solutions [2] - The company's products and services aim to ensure product integrity, enhance patient and worker safety, and improve overall quality of life globally [2]

Revenue Performance - For the six months ended September 30, 2025, the company achieved revenue growth of 3.7% compared to the prior year, driven by the Calibration Solutions, Biopharmaceutical Development, and Sterilization and Disinfection Control divisions [94]. - The Clinical Genomics division experienced a revenue decline of 6.4% for the six months ended September 30, 2025, primarily due to trade tensions and unfavorable macroeconomic conditions in China [94]. - Revenues for the three months ended September 30, 2025, were $60,737,000, representing a 5.0% increase from $57,833,000 in the prior year [102]. - The Sterilization and Disinfection Control division reported revenues of $47.5 million for the six months ended September 30, 2025, with a gross profit margin of 69.5% [101]. - The Biopharmaceutical Development division generated revenues of $25.4 million for the same period, with a gross profit margin of 56.8% [101]. - The Calibration Solutions division achieved revenues of $25.9 million, reflecting a 7.7% organic revenue growth for the six months ended September 30, 2025 [101]. - The Sterilization and Disinfection Control division's revenues declined 0.4% for the three months ended September 30, 2025, primarily due to lower-than-expected order fulfillments [105]. - The Biopharmaceutical Development division's revenues increased 17.3% for the three months ended September 30, 2025, driven by higher sales of Peptides instruments [110]. - Revenues for the Calibration Solutions division increased 10.7% for the three months ended September 30, 2025, due to ongoing commercial efforts and price increases [114]. - Clinical Genomics division revenues declined 3.1% for the three months ended September 30, 2025, primarily due to lower sales to customers in China [118]. Operating Expenses and Profitability - Consolidated gross profit as a percentage of revenues decreased by 1.0 percentage point to 61.7% for the first half of fiscal year 2026, impacted by the weakening of the U.S. dollar and tariffs [95]. - Operating expenses increased by 4.5% for the six months ended September 30, 2025, largely due to higher personnel expenses and non-cash stock-based compensation [98]. - Operating expenses increased 2.1% for the three months ended September 30, 2025, influenced by the weakening of the U.S. dollar against the euro and Swedish krona [121]. - Selling expenses decreased 0.5% for the three months ended September 30, 2025, primarily due to lower personnel and training costs [123]. - General and administrative expenses increased 1.7% for the three months ended September 30, 2025, driven by higher estimated uncollectible accounts receivable in China [125]. - Gross profit as a percentage of revenues for the Biopharmaceutical Development division decreased 2.0 percentage points for the three months ended September 30, 2025, primarily due to tariffs and unfavorable product mix [112]. Cost Management and Future Outlook - The company expects to realize annualized cost reductions of approximately $2.3 million starting in the third quarter of fiscal year 2026, following headcount reductions and other cost-saving initiatives [97]. - Research and development expenses increased by 8.9% to $5.048 million for the three months ended September 30, 2025, and by 7.1% to $10.032 million for the six months ended September 30, 2025, compared to the prior year periods [128]. - Interest expense decreased by 5.2% to $2.862 million for the three months ended September 30, 2025, and by 13.7% to $5.060 million for the six months ended September 30, 2025, primarily due to lower interest rates and outstanding debt levels [129]. - The company expects to incur approximately $11.6 million in cash interest expense over the next twelve months [140]. Cash Flow and Working Capital - Net cash provided by operating activities was $10.115 million for the six months ended September 30, 2025, a decrease of $5.9 million compared to the prior year [148]. - Working capital improved to $49.1 million as of September 30, 2025, from negative working capital of $(61.3) million as of March 31, 2025, due to the settlement of $97.5 million in principal related to Notes [139]. - Cash used in investing activities decreased to $(2.101) million for the six months ended September 30, 2025, compared to $(2.679) million in the prior year [149]. Dividends and Shareholder Returns - The company paid dividends of $0.16 per share during the three months ended September 30, 2025, and announced a quarterly cash dividend of $0.16 per share payable on December 15, 2025 [142]. Market Risk and Global Operations - Approximately 53% of the company's revenues were earned outside the United States during the six months ended September 30, 2025, highlighting its global operations [93]. - There were no material changes to the company's market risk exposure during the three months ended September 30, 2025 [156]. - The company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, contains detailed disclosures about market risk exposure [156]. Organic Revenue Growth - Total company organic revenue growth for the three months ended September 30, 2025, was 5.0%, compared to 8.8% in the same period of 2024 [155]. - Biopharmaceutical Development segment showed organic revenue growth of 17.3% for the three months ended September 30, 2025, down from 28.9% in 2024 [155]. - Clinical Genomics segment experienced a decline in organic revenue of (3.1%) for the three months ended September 30, 2025, compared to a decline of (26.0%) in 2024 [155]. - For the six months ended September 30, 2025, total company organic revenue growth was 3.7%, down from 11.7% in 2024 [155]. - Calibration Solutions segment reported organic revenue growth of 7.7% for the six months ended September 30, 2025, compared to 5.6% in 2024 [155]. - Sterilization and Disinfection Control segment had organic revenue growth of 5.2% for the six months ended September 30, 2025, down from 36.8% in 2024 [155]. - Clinical Genomics segment's organic revenue decline was (6.4%) for the six months ended September 30, 2025, compared to (20.8%) in 2024 [155]. Goodwill and Foreign Currency - The carrying values of goodwill associated with the Clinical Genomics and Peptides reporting units were $17.1 million and $13.7 million, respectively, as of September 30, 2025 [146]. - The company recognized unrealized foreign currency gains of approximately $6.1 million during the six months ended September 30, 2025, related to an intercompany loan [130].

Revenue Performance - Total revenues for 2Q26 were $60,737, an increase of 5.0% compared to 2Q25[9] - Biopharmaceutical Development (BPD) revenues grew 17.3% to $13,920, driven by higher sales of Peptides instruments[12] - Clinical Genomics (CG) revenues declined 3.1% to $11,140, with a significant 58% decrease in China[13] - Calibration Solutions (CS) revenues increased 10.7% to $13,570, supported by strong commercial execution[11] - Total revenues growth for the three months ended September 30, 2025, was 5.0% compared to the same period in 2024[26] - Organic revenues growth (non-GAAP) for the six months ended September 30, 2025, was 3.7%[26] - Currency translation impact on organic revenues growth was (1.3)% for the three months ended September 30, 2025[26] Profitability - Non-GAAP core organic revenue growth was 3.7%, with operating income increasing 34.7% to $4,724[8] - Profitability, measured by adjusted operating income (AOI) excluding unusual items, was 25.1% of revenues, up from 24.8% in 2Q25[5] - Non-GAAP adjusted operating income (AOI) for the three months ended September 30, 2025, was $14,385,000, an increase from $13,413,000 in 2024[25] - AOI per share - basic (non-GAAP) for the three months ended September 30, 2025, was $2.61, up from $2.48 in 2024[25] - AOI excluding unusual items (non-GAAP) for the three months ended September 30, 2025, was $15,233,000, compared to $14,352,000 in 2024[25] - The company reported a GAAP operating income of $4,724,000 for the three months ended September 30, 2025, compared to $3,508,000 in 2024[25] Cost Management - The company reduced annualized costs by $3.2 million, including $2.1 million in Clinical Genomics, to align with market conditions[5] - The company plans to reinvest approximately $0.9 million of cost savings into Sterilization and Disinfection Control (SDC) for long-term growth[5] Financial Position - The total net leverage ratio was 3.02 as of September 30, 2025[9] - Total current assets decreased to $97,433,000 as of September 30, 2025, from $102,685,000 on March 31, 2025[24] - Stockholders' equity increased to $178,468,000 as of September 30, 2025, compared to $159,830,000 on March 31, 2025[24] - Total liabilities decreased to $251,883,000 as of September 30, 2025, from $273,518,000 on March 31, 2025[24] Future Outlook - Future revenue growth is expected to continue in 3Q26, despite macroeconomic uncertainties[4]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if ad-blockers are enabled, indicating a need to disable them for proper access [1]

Company Overview - Mesa Laboratories, Inc. is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [2] - The company offers products and services aimed at ensuring product integrity, increasing patient and worker safety, and improving the quality of life globally [2] Financial Announcement - Mesa Laboratories, Inc. will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025 [1]